| 2026-08-17 | Press release | Castle Biosciences Approved for Dual Listing on Nasdaq Texas |
| 2026-07-30 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-30 | Press release | Castle Biosciences Reports Second Quarter 2026 Results |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-22 | Press release | Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference |
| 2026-07-14 | Press release | Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test |
| 2026-07-09 | Press release | Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday |
| 2026-06-25 | Press release | DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Nod |
| 2026-06-23 | Press release | Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal |
| 2026-06-19 | Press release | Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-16 | Press release | Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with B |
| 2026-05-29 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-13 | Press release | Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference |
| 2026-05-12 | Press release | Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation |
| 2026-05-06 | Press release | Castle Biosciences Reports First Quarter 2026 Results |
| 2026-05-06 | Press release | Castle Biosciences Reports First Quarter 2026 Results |
| 2026-05-06 | Press release | Castle Biosciences Reports First Quarter 2026 Results |
| 2026-05-06 | Deck | Investor presentation · Q1 2026 · May 2026 |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-05 | Supplement | Quarterly Factsheet · Q1 2026 |
| 2026-05-04 | Press release | New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barre |
| 2026-04-15 | Press release | Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 |
| 2026-04-08 | Proxy | Definitive proxy statement |
| 2026-04-01 | Annual report | View Featured Report · FY 2025 |
| 2026-03-27 | Press release | Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Perso |
| Transcript | Earnings call transcript |
| 2026-03-04 | Press release | Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients |
| 2026-03-01 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-26 | Press release | Castle Biosciences Reports Fourth Quarter and Full-Year 2025 Results |
| 2026-02-26 | Deck | Corporate Presentation · Q4 2025 |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-19 | Press release | Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis |
| 2026-02-05 | Press release | Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 |
| 2026-01-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-11 | Press release | Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results |
| 2026-01-09 | Deck | Castle Preliminary Fourth Quarter and Full-Year 2025 Results Slide Presentation |
| 2025-11-03 | Press release | Castle Biosciences Reports Third Quarter 2025 Results |